ClinicalTrials.Veeva

Menu

Sensitivity of the Home Macular Perimeter (HMP)

Notal Vision logo

Notal Vision

Status

Completed

Conditions

Choroidal Neovascularization
Age Related Macular Degeneration

Study type

Observational

Funder types

Industry

Identifiers

NCT00604071
HMP-V4
20071801

Details and patient eligibility

About

estimate the sensitivity of the HMP test in identifying visual field functional defects in subjects with CNV secondary to AMD

Full description

The HMP device is intended to aid patients in identifying their visual abnormalities and in addition to their own symptoms or Amsler grid use and aid in their prompt referral to eye care professional examination so clinical diagnosis can be made. As such the goal of the clinical plan is to demonstrate that patients who have CNV do demonstrate visual field abnormalities when tested with the HMP

Enrollment

99 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Capable and willing to sign a consent form and participate in the study
  • subjects with AMD related lesions: New onset (up to 60 days) non-treated CNV
  • Age >50 years
  • VA with habitual correction >20/200 in study eye
  • Familiar with computer usage

Exclusion criteria

  • Evidence of macular disease other than AMD or glaucoma in the study eye
  • Presence of any significant media opacity that precludes a clear view of the macular area as identified in the study eye by biomicroscopy, CFP, or FA
  • Any non-macular related ocular surgery performed within 3 months prior to study entry in the targeted eye
  • Inability to tolerate intravenous FA
  • Participation in another study with the exclusion of AREDS study

Trial design

99 participants in 1 patient group

1
Description:
subjects with AMD related lesions: New onset (up to 60 days) non-treated CNV

Trial contacts and locations

10

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems